Comparative analysis of serological survey results of mumps in healthy people in Changsha in 2016 and 2024
10.3969/j.issn.1006-2483.2026.05.011
- VernacularTitle:2016年与2024年长沙市健康人群流行性腮腺炎血清流行病学调查结果对比分析
- Author:
Li LI
1
;
Yaman LI
1
;
Ying ZHANG
1
;
Meiling LUO
1
;
Haoyue QIU
1
;
Haobin YANG
2
;
Yancong CHEN
2
;
Qin ZENG
2
;
Jing HE
2
;
Wenqian XU
2
Author Information
1. Changsha Center for Disease Control and Prevention, Changsha, Hunan 410000, China
2. School of Nursing, Wuhan University, Wuhan, Hubei 430071, China
- Publication Type:Journal Article
- Keywords:
Mumps;
Immune strategy adjustments;
IgG antibody;
Mumps containing vaccine
- From:
Journal of Public Health and Preventive Medicine
2026;37(5):51-55
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the serological survey results of Changsha City in 2016 and 2024, and to investigate the short-term impact of adjusting the immunization program with two doses of mumps containing vaccine on the mumps antibody levels of healthy individuals in Changsha City. Methods Using the relevant data and samples from the mumps serological surveys conducted in 2016 and 2024, serum mumps IgG antibodies were quantitatively detected by enzyme-linked immunosorbent assay. The results from these two surveys were analyzed and compared using SPSS 25.0 software. Results The survey included 1 512 participants in 2016 and 1 398 in 2024. In 2024, both the seropositivity rate and IgG antibody levels against mumps in the healthy population were significantly higher than those in 2016 (all P<0.01). Specifically, the seropositivity rates and IgG antibody levels in the age groups of 8–17 months, 18 months–2 years, 3–4 years, and 5–9 years were significantly higher in 2024 compared to 2016 (all P < 0.001). However, among the participants in 2024, the 15–19 years age group showed relatively low seropositivity rate and IgG antibody levels. Conclusion Following the adjustment of the two-dose MuCV immunization strategy, the mumps IgG antibody levels among children aged 8 months to 9 years in Changsha have increased. It is necessary to continue implementing the routine two-dose MuCV vaccination strategy and to explore the necessity of strengthening and supplementing immunization for key groups, including the high-risk 5–9-year-old population and the immunologically vulnerable 15–19-year-old population.
